These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25426996)

  • 21. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
    Yamazaki S; Ichimura S; Iwamoto J; Takeda T; Toyama Y
    J Bone Miner Metab; 2004; 22(5):500-8. PubMed ID: 15316873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative contribution of HIV infection, demographics and body mass index to bone mineral density.
    Cotter AG; Sabin CA; Simelane S; Macken A; Kavanagh E; Brady JJ; McCarthy G; Compston J; Mallon PW;
    AIDS; 2014 Sep; 28(14):2051-60. PubMed ID: 25265073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
    HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA; Bilezikian JP; Kung AW; Ahmed MM; Dubois SJ; Ho AY; Schussheim D; Rubin MR; Shaikh AM; Silverberg SJ; Standish TI; Syed Z; Syed ZA
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3319-25. PubMed ID: 15240609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy.
    Bolland MJ; Horne AM; Briggs SE; Thomas MG; Reid IR; Gamble GD; Grey A
    Calcif Tissue Int; 2019 Oct; 105(4):423-429. PubMed ID: 31250043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B; San Martin J; Crans G; Pavo I
    J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in bone mineral density and metabolism in women: evaluation of bodily characteristics, bone metabolic markers and bone mineral density.
    Iida T; Harada T; Ishizaki F; Nitta Y; Aoi S; Ikeda H; Chikamura C; Shiokawa M; Nitta K
    Hiroshima J Med Sci; 2013 Sep; 62(3):49-53. PubMed ID: 24279122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of bone mineral density in stable kidney transplant recipients.
    Gupta AK; Huang M; Prasad GV
    J Nephrol; 2012; 25(3):373-83. PubMed ID: 21928224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.
    Bloch M; Tong WW; Hoy J; Baker D; Lee FJ; Richardson R; Carr A;
    HIV Med; 2014 Jul; 15(6):373-80. PubMed ID: 24460797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship among VDR (BsmI and FokI), COLIA1, and CTR polymorphisms with bone mass, bone turnover markers, and sex hormones in men.
    Braga V; Sangalli A; Malerba G; Mottes M; Mirandola S; Gatti D; Rossini M; Zamboni M; Adami S
    Calcif Tissue Int; 2002 Jun; 70(6):457-62. PubMed ID: 12016463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
    Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
    HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).
    Negredo E; Domingo P; Pérez-Álvarez N; Gutiérrez M; Mateo G; Puig J; Escrig R; Echeverría P; Bonjoch A; Clotet B
    J Antimicrob Chemother; 2014 Dec; 69(12):3368-71. PubMed ID: 25125679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
    Kwak MK; Lee EJ; Park JW; Park SY; Kim B-; Kim TH; Suh K; Koh J-; Lee SH; Byun D-
    Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing bone mineral density in ARV-naive patients at Sanglah Hospital, Bali.
    Masyeni S; Utama S; Somia A; Widiana R; Merati TP
    Acta Med Indones; 2013 Jul; 45(3):175-9. PubMed ID: 24045386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone mineral density and bone turnover in patients with psoriatic arthritis.
    Borman P; Babaoğlu S; Gur G; Bingol S; Bodur H
    Clin Rheumatol; 2008 Apr; 27(4):443-7. PubMed ID: 17876648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.